Leukemia – NCI-04-C-0121
Dr. Robert J. Kreitman
Principal Investigator
NCI is currently conducting the following trial for patients with chronic lymphocytic leukemia or prolymphocytic leukemia. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Kreitman and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
- Patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and 5
- Treatment repeats every 28 days for up to 6 courses in the absence of disease progression, neutralizing antibodies (i.e., > 75% of the activity of 1μg/mL of LMB-2 immunotoxin), or unacceptable toxicity
- Patients who achieve a complete response receive up to 2 additional courses of LMB-2 immunotoxin
- Patients who relapse after achieving a complete or partial response for more than 2 months are eligible for retreatment as described above
- Patients are followed every 3-12 months until disease progression
Why is this trial important?
Patients with chronic lymphocytic leukemia have many options for therapy but many have malignant cells that do not respond well to any standard therapy. These cells often display the marker CD25, which makes them potential targets for the recombinant immunotoxin LMB-2.
Back to Top
